Johnson & Johnson (NYSE:JNJ) will increase its dividend from last year's comparable payment on the 10th of June to $1.30. This will take the annual payment to 3.4% of the stock price, which is ...

Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Health care giantJohnson & Johnson said on Wednesday the US Food and Drug Administration (FDA) has approved its drug to treat patients aged 12 years and older with an immune-mediated disorder.

Company seeks approval for new schedules to improve patient convenience Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency (EMA) ...

Mumbai, Maharashtra, India: Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, has onboarded Qure.ai, a global leader in artificial intelligence (AI) for healthcare ...

Johnson & Johnson took a shot at the Trump administration’s tariff policy and outlined its plans for how it will absorb the negative impact. But even with the extra costs, which the medical ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28 th, 2025. Management will ...

Investing.com -- S&P Global Ratings has confirmed the ’AAA’ long-term issuer credit rating and unsecured debt ratings for pharmaceutical and medical device company, Johnson & Johnson (NYSE:JNJ).

New social impact platform J&J CareCommunity aims to collaboratively help address global nursing challenges Johnson & Johnson today announced the expansion of its efforts to champion the nursing ...

These two policies could have major impacts on AbbVie, Lilly, and Johnson & Johnson. Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Stock market ...

(RTTNews) - Johnson & Johnson (JNJ) announced the FDA has approved IMAAVY, a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis. The approval is supported ...

77% of genital psoriasis patients saw clear/almost clear skin vs. 21% on placebo after 16 weeks. PN-881 showed 70x greater potency than secukinumab in vitro and effective reduction in skin ...